Extendicare Inc.
TSX:EXE.TOMedical - Care Facilities
+$0.86 today
- Market cap
- $2.74B
- Beta
- 1.16
- P/E (TTM)
- 26.4
- EPS (TTM)
- $1.28
- Dividend yield
- 1.51%
Volume 0.86M
Average 0.34M
EXE.TO Accounts Receivables
Cash effect of the change in amounts owed by customers; growing receivables consume cash.
Extendicare Inc.TSX: EXE.TO
Accounts Receivables · Q2 FY2026 · quarter ended Jun 2026
Accounts receivables growth accelerates
Q2 FY2026 accounts receivables of CA$1.82M (cash outflow) rose 48.6% year over year, ahead of the -80.3% change in trailing-twelve-month accounts receivables. Sequentially, it fell 89.4% from the prior quarter. Over 3 fiscal years it compounded at +66.2% a year.
Context
- Accounts receivables amounted to 1.1% of revenue in FY2025, up 0.9 pp from a year earlier.
- Accounts receivables increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +48.6% holds above the trailing-twelve-month pace of -80.3%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Receivables history
CAD · from the cash flow
- Latest · FY2025
- 18.56M CAD
- Year-over-year change
- +618.0%
| Period | Period end | Accounts Receivables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 18.56M | +618.0% |
| FY2024 | 2024-12-31 | (3.58M) | +87.7% |
| FY2023 | 2023-12-31 | (29.2M) | -822.4% |
| FY2022 | 2022-12-31 | 4.04M | +129.4% |
| FY2021 | 2021-12-31 | (13.77M) | — |
Accounts Receivables vs competitors
How EXE.TO compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts receivables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of -80.3% is the 6th highest of 7, against a peer median of +145.4%.
- Accounts receivables amounts to 0.1% of revenue for EXE.TO, versus a peer median of 1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | CA$39.31M CAD | +177.5% | — | 2.7% | |
| LTM Mar 2026 | $19.83M USD | +490.3% | +113.0% | 12.4% | |
| LTM Feb 2026 | $9.62M USD | -18.4% | +45.0% | 1.1% | |
| LTM Mar 2026 | $6.55M USD | -297.0% | +15.7% | 2.1% | |
| LTM Jun 2026 | CA$1.78M CAD | -80.3% | +66.2% | 0.1% | |
| LTM Mar 2026 | CA$460K CAD | +237.7% | -45.3% | 0.1% | |
| LTM Sep 2026 | CA$141K CAD | +113.3% | — | 0.0% | |
| Peer median (excluding EXE.TO) | — | +145.4% | +30.3% | 1.6% | |
Competitors are the stored peer set for EXE.TO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 11.5M | 69.55M | 33.98M | 75.21M | 96.66M |
| Depreciation & Amortization | 38.57M | 32.12M | 32.23M | 33.34M | 37.25M |
| Deferred Income Tax | 6.61M | (46K) | 4.01M | 23.86M | (7.87M) |
| Stock-Based Compensation | 3.7M | 2.64M | 4.2M | 1.89M | 696K |
| Change in Working Capital | 9.29M | 54.06M | (41.2M) | 22.85M | 57.02M |
| Accounts Receivables | (13.77M) | 4.04M | (29.2M) | (3.58M) | 18.56M |
| Inventory | (11.1M) | 0 | 0 | 0 | 0 |
| Accounts Payables | 11.1M | 48.62M | (14.43M) | 31.92M | 25.24M |
| Other Working Capital | 23.05M | 1.4M | 2.43M | (5.48M) | 13.22M |
| Other Non-Cash Items | (10.59M) | (59.46M) | (9.94M) | (13.51M) | (18.54M) |
| Operating Cash Flow | 59.08M | 98.87M | 23.28M | 143.64M | 165.21M |
| Capital Expenditures | (65.18M) | (101.63M) | (129.41M) | (41.95M) | (101.81M) |
| Acquisitions (Net) | 0 | 253.14M | 0 | 0 | (75.12M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | (1.08M) |
| Sales of Investments | 0 | 0 | 0 | 29.47M | 57.36M |
| Other Investing Activities | 5.79M | 4.13M | 44.96M | 3.37M | 1.63M |
| Investing Cash Flow | (59.39M) | 155.64M | (84.45M) | (9.11M) | (119.02M) |
| Debt Repayment | (29.98M) | (114.23M) | 18.67M | (44.53M) | 30.61M |
| Common Stock Issued | 0 | 0 | 0 | 0 | 191.52M |
| Common Stock Repurchased | 0 | (35.02M) | (11.06M) | 0 | 0 |
| Dividends Paid | (42.99M) | (42.55M) | (40.43M) | (40.02M) | (41.7M) |
| Other Financing Activities | (1.86M) | (56K) | 1.89M | (3.31M) | 0 |
| Financing Cash Flow | (74.84M) | (191.86M) | (30.93M) | (87.87M) | 180.43M |
| Effect of Forex Changes | (184K) | 155K | 0 | 0 | 0 |
| Net Change in Cash | (75.33M) | 62.65M | (92.1M) | 46.66M | 226.63M |
| Free Cash Flow | (6.1M) | (2.76M) | (106.13M) | 101.69M | 63.4M |
Extendicare Inc.
TSX:EXE.TO
Intrinsic Alpha fair value
Locked
Current Price
$28.81
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.